NEW TECHNOLOGY

Selectively infective phage (SIP) technology: A novel method for in vivo selection of interacting protein-ligand pairs

STEFANIA SPADA & ANDREAS PLÜCKTHUN Biochemisches Institut der Universität Zürich, Winterthurerstr. 190, CH-8057 Zürich, Switzerland Correspondence should be addressed to A.P. (email: plueckthun@biocfebs.unizh.ch)

We describe here a new technology, selectively infective phages (SIP)¹⁻⁸, which can be used in screening large libraries only N1, is stimulated by high Ca²⁺ concentrations, does not and in driving molecular evolution within these libraries. SIP is require F-pili and must therefore involve direct binding of N1 related to phage display technology using filamentous phages^{9,10}, where a protein or peptide of interest is fused to a phage coat protein and, thus, displayed on the outer surface of the phage, while its genetic information is contained in the phage DNA. In contrast to phage display, the phage particles are rendered non-infective in SIP by disconnecting the N-terminal domains (N1 and N2) of the phage g3p coat protein (Fig. 1) — those involved in docking and bacterial cell penetration — from the C-terminal domain (CT), which caps the end of the phage. The N- and C-terminal domains are then each fused to one of the interacting partners being studied. One partner is thus displayed on the phage surface associated with CT, while the other is genetically fused or chemically coupled to the Ndomain(s), thus constituting a separate "adapter" molecule. Only when the specific protein-ligand interaction occurs between the partners is the g3p reconstituted and does the phage particle regain its infectivity, and the genetic information of a successful binder is propagated. In contrast, in phage display the penetration domain whole phage binds and can be eluted from an immobilized target molecule, whereupon, since it remains infective, it can inject its DNA into bacterial cells and be amplified. The main limitation of phage display at present is the occurrence of non-specific adsorption of phages binding during the stage¹¹, necessitating an enrichment over several rounds and individually tailored washing and adapter bacterial cell elution conditions.

main⁶. Two pathways of infection are possible: One requires to the bacterial surface⁶. The second requires N2 and F-pili, but no Ca²⁺, suggesting a docking of N2 to the pili⁶. Both pathways can be used in SIP; the second one is much more efficient, however⁶. The influence of different g3p domain rearrangements in SIP has been studied. In a fluorescein/anti-fluorescein scFv model system, purified N1 or N1-N2 domains, chemically coupled to the antigen fluorescein (N1-Ag and N1-N2-Ag), were used in combination with scFv-"short" (Fig. 2a) or scFv-"medium" phages (Fig. 2b) to recreate a wt g3p interrupted at various positions⁶. As shown in Fig. 2*c*, infectivity as a function of adapter concentration was different in the two cases; furthermore, N1-N2 inhibits the entry of wt phage into cells with a half-inhibitory concentration two orders of magnitude lower than N1 alone⁶. At low N1-N2-Ag concentrations the phage is not sufficiently saturated with ligand-adapter to mediate infectivity in SIP selection, while at high concentrations the bacteria themselves become saturated, blocking infection⁶. anchoring domain Therefore, very low concentrations of N1-N2-Ag are needed and the system will select for high wt phage affinity binders — provided, of course, such molecules exist in the library under study. In the case of the N1display phage b Ag adapter molecule, higher concentrations can and must be used in order to overcome the SIP infection effilower ciency of the system⁶, while possibly allowing selection for lower non-infective phage binding affinity pairs. This requirement for a high concentration of

binding domain



Variations of SIP

694

The g3p N1 domain is absolutely essential for the infection process^{6,12}, whereas a residual infectivity is observed in the absence of the N2 dospecific protein-ligand interaction

N1 may reflect a low-Fig. 1 Comparison of wt phage, display phage and SIP. a, wt phage: Infectivity is meaffinity binding to diated by the wt g3p, which is enlarged. It consists of two N-terminal domains, N1 (1-68 Escherichia coli in the abaa) and N2 (87-217 aa), and a C-terminal domain, CT (257-406 aa), linked by two sence of pili and/or a neglycine-rich linkers, G1 and G2. b, Display phage: CT fused to the displayed protein cessity for multivalent (encoded on a phagemid that gets packaged) and wt g3p (encoded by a helper phage) are both present on the phage, which remains infective. c, SIP: The specific proteinbinding to the bacteria ligand interaction is essential to restore infectivity of an otherwise non-infective phage. — requiring simultane-

NATURE MEDICINE • VOLUME 3 • NUMBER 6 • JUNE 1997

NEW TECHNOLOGY

ous occupation of all cognate ligand-binding sites on the phage. In the absence of coupled antigen, no infectivity was observed⁶, demonstrating that the N-terminal domains must be physically coupled to the phage for infection.

For SIP to work, the phage must be strictly non-infective. Using a phagemid/helper phage system, an unpackageable g3p expression plasmid must be used in combination with a g3pdeleted helper phage, but all tested plasmids appeared to con-

tain cryptic packaging signals⁴ and thus gave rise to background infectivity. These problems are aovercome by introducing the g3p fusion protein directly into a single genetic package, the phage genome⁴.



hemagglutinin peptide, was used as a model where both peptide and antibody were encoded in the same phage genome⁴, resulting in a very clean selection of the desired Ab–Ag pair. An anti-fluorescein antibody/antigen system was used as the first example of a non-peptidic antigen being coupled to purified g3p N-terminal domains⁶. In the latter case, up to 10⁶ antigenspecific infection events were observed from 10¹⁰ input phages, compared to only one antigen-independent event. No back-

> ground infection was observed in the absence of antigen or in the presence of an antibody of different specificity in the latter two examples, presumably due to the use of phage vectors as the sole replicons and thus in strict absence of any wt g3p. In a Fab library made from B cells of gp120 seronegative donors, with only the N1 domain fused to the V3 loop peptide, three rounds of traditional phage panning yielded no antibodies against the antigen, but half of the phages gave positive ELISA signals after three rounds of SIP². The ability to enrich for affinity or even kinetic constants has been tested using six different Fab fragments against the V3 loop peptide as a model library, with high-affinity antibodies being preferentially selected⁵. High-affinity antibodies were also enriched from a library that had been made from B cells after

SIP experiments can be carried bout in vivo or in vitro (Fig. 3): In the former approach the phage or phagemid encodes both interacting molecules (for example, antibody-antigen) in the same Cvector^{3,4,7} (Fig. 3*a*), and the protein-ligand interaction occurs in the bacterial periplasm; the infective phage particle is extruded from the cell and can be harvested and used to infect different bacteria. The simplicity of design of the experiment is counteracted to some extent by the lack of experimental control over parameters such as concentrations, incubation times and the infection process itself.

These factors can be controlled

[N1-Ag] (•) or [N1-N2-Ag] (0) (M)

in the *in vitro* SIP experiment (Fig. 3*b*). In this case, the adapter protein is prepared from a separate *E. coli* culture, either by secretion^{2,5,8} or by *in vitro* refolding⁶. This approach broadly extends the range of applications of SIP, as, in addition to genetically fused peptidic antigens, non-pep**Fig. 2** Two different g3p arrangements in SIP and their respective infectivity as a function of adapter concentration are shown. *a*, N1-N2-Ag in combination with scFv-"short" phage, with g3p interrupted between N2 and CT. The same infectivity was observed when scFv-"medium" phage was used instead. *b*, N1-Ag with scFv-"medium" phage, where g3p is interrupted between N1 and N2. Fewer colonies were found with N1-Ag and scFv-"short" phage. *c*, Infectivity (number of colonies) of combinations (*a*) and (*b*) as a function of adapter concentration. (Adapted from ref. 6.)

tidic antigens can now be chemically coupled to the N-terminal domains⁶. The adapter is then incubated with the non-infective phage library, and added to the bacteria.

Examples of SIP studied

The SIP system has been tested with both proteins and peptides. The leucine-zipper motifs of the jun and fos proteins, with both helices flanked by cysteine residues¹³, were used as a model system³ in which the heteromeric interaction between the two peptides restored the infectivity of the phage. An enrichment of up to 200-fold over non-interacting pairs was observed after one round. Furthermore, zipper-like domains that pair with the jun-zipper domain have been selected from a human cDNA library⁷. With an anti-lysozyme Fab fragment model system, in association with an N1-lysozyme adapter molecule, a specific enrichment factor of approximately 10¹⁰ was observed after only two rounds of selection². The antibody 17/9, specific for a in vitro immunization⁸.

Further prospects

A requirement of SIP appears to be a high affinity between protein and ligand, and all of the systems studied thus far have had dissociation constants of at least 10⁻⁸ M. It is not yet clear, how-

ever, what the minimum affinity necessary for significant infectivity will be. Further investigations will also have to be carried out to test the, initially encouraging, apparent ability to select for kinetic parameters of ligand binding, and to investigate the dependency of infectivity on properties of the proteins, such as thermodynamic stability and expression rate, as well as the size limits of protein–ligand complexes usable in SIP.

Since SIP is definitely compatible with disulfide formation, it complements the two-hybrid system¹⁴ well for library screening, as the latter is designed for use with nuclear and cytoplasmic proteins. The toxicity of certain proteins, when displayed on phage, is a limitation SIP shares with phage display. Furthermore, in SIP care must be taken, especially during *in vivo* SIP experiments, in phage handling and in controlling rare recombination events in the phage that could restore infective wt-like g3p (ref. 4). These challenges are to be contrasted with the numerous ad-

NATURE MEDICINE • VOLUME 3 • NUMBER 6 • JUNE 1997



NEW TECHNOLOGY



Fig. 3 In vivo versus in vitro SIP. *a*, In the *in vivo* approach both interacting partners are encoded in the same genetic vector and co-expressed in the same bacterium where they can interact. *b*, In the *in vitro* approach the N-terminal domains of g3p and the displaying phage are produced in separate cells. The antigen, fused or chemically coupled to the N-terminal domains, needs to be incubated with the non-infective phage before they are used to infect bacteria.



vantages that SIP has over phage display. No solid-phase interaction with any support is necessary in SIP, limiting the potential of the occurrence of non-specific interactions and eliminating the need for elution. In addition, the low background infectivity observed with some of the SIP systems^{4,6} demonstrates that SIP can be an extremely effective and highly specific method of selecting for cognate interaction events. Furthermore, the exciting possibility of simultaneous screening of two interacting libraries by *in vivo* SIP might broaden the ability to identify interacting receptor–ligand pairs.

Acknowledgments

The authors wish to thank G. Wall and C. Krebber for helpful suggestions and critical reading of the manuscript.

- 4. Krebber, C., Spada, S., Desplancq, D. & Plückthun, A. Co-selection of cognate antibody-antigen pairs by selectively-infective phages. *FEBS Let.* **377**, 227–231 (1995).
- Duenas, M., Malmborg, A.-C., Casalvilla, R., Ohlin, M. & Borrebaeck, C.A.K. Selection of phage displayed antibodies based on kinetic constants. *Mol. Immunol.* 33, 279–285 (1996).
- Krebber, C. *et al.* Selectively-infective phage (SIP): A mechanistic dissection of a novel *in vivo* selection for protein–ligand interactions. *J. Mol. Biol.* 268, 619–630 (1997).
- Gramatikoff, K., Schaffner, W. & Georgiev, O. The leucine-zipper of c-Jun binds to ribosomal protein L18a: A role in Jun protein regulation? *Biol. Chem.* 376, 321–325 (1995).
- Duenas, M. et al. In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display. Immunology 89, 1–7 (1996).
- 9. Smith, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985).
- 10. Dunn, I.S. Phage display of proteins. Current Opin. Biotechnol. 7, 547-553 (1996).
- Adey, N.B., Mataragnon, A.H., Rider, J.E., Carter, J.M. & Kay, B.K. Characterization of phage that bind plastic from phage-displayed random peptide libraries. *Gene* 156, 27–31 (1995).
- 1. Krebber, C., Moroney, S., Plückthun, A. & Schneider, C. European Patent Application EP 93102484 (1993).
- Duenas, M. & Borrebaeck, C.A.K. Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. *Bio/Technology* 12, 999–1002 (1994).
- 3. Gramatikoff, K., Georgiev, O. & Schaffner, W. Direct interaction rescue, a novel filamentous phage technique to study protein–protein interactions. *Nucleic Acids Res.* 22, 5761–5762 (1994).
- 12. Stengele, I., Bross, P., Garces, X., Giray, J. & Rasched, I. Dissection of functional domains in phage fd adsorption protein. J. Mol. Biol. 212, 143–149 (1990).
- Crameri, R. & Suter, M. Display of biologically active proteins on the surface of filamentous phages: cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production. *Gene* 137, 69–75 (1993).
- Bai, C. & Elledge, S.J. Gene identification using the yeast two-hybrid system. Methods Enzymol. 273, 331–347 (1996).

696

NATURE MEDICINE • VOLUME 3 • NUMBER 6 • JUNE 1997